Northern Trust
ORIC icon

Northern Trust’s Oric Pharmaceuticals ORIC Stock Holding History

Northern Trust’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.73M Buy
806,304
+95,443
+13% +$865K ﹤0.01% 2290
2026
Q1 		$9.01M Sell
710,861
-174,614
-20% -$1.98M ﹤0.01% 2134
2025
Q4 		$7.24M Sell
885,475
-3,060
-0.3% -$35.2K ﹤0.01% 2253
2025
Q3 		$10.7M Buy
888,535
+487,581
+122% +$5.13M ﹤0.01% 2084
2025
Q2 		$4.07M Sell
400,954
-145,792
-27% -$979K ﹤0.01% 2576
2025
Q1 		$3.05M Sell
546,746
-7,247
-1% -$63.4K ﹤0.01% 2688
2024
Q4 		$4.47M Buy
553,993
+28,079
+5% +$258K ﹤0.01% 2572
2024
Q3 		$5.39M Buy
525,914
+166,888
+46% +$1.65M ﹤0.01% 2430
2024
Q2 		$2.54M Buy
359,026
+5,685
+2% +$50.9K ﹤0.01% 2771
2024
Q1 		$4.86M Buy
353,341
+144
+0% +$1.71K ﹤0.01% 2472
2023
Q4 		$3.25M Buy
353,197
+10,297
+3% +$74.5K ﹤0.01% 2722
2023
Q3 		$2.07M Buy
342,900
+4,969
+1% +$40.7K ﹤0.01% 2918
2023
Q2 		$2.62M Buy
337,931
+264,208
+358% +$1.5M ﹤0.01% 2854
2023
Q1 		$420K Buy
73,723
+791
+1% +$4.13K ﹤0.01% 3537
2022
Q4 		$430K Sell
72,932
-307
-0.4% -$1.04K ﹤0.01% 3557
2022
Q3 		$234K Buy
73,239
+714
+1% +$2.86K ﹤0.01% 3811
2022
Q2 		$325K Sell
72,525
-226,333
-76% -$903K ﹤0.01% 3692
2022
Q1 		$1.6M Sell
298,858
-14,925
-5% -$134K ﹤0.01% 3204
2021
Q4 		$4.61M Sell
313,783
-3,025
-1% -$47.2K ﹤0.01% 2731
2021
Q3 		$6.62M Buy
316,808
+38,917
+14% +$789K ﹤0.01% 2559
2021
Q2 		$4.92M Buy
277,891
+47,134
+20% +$1.03M ﹤0.01% 2849
2021
Q1 		$5.65M Sell
230,757
-6,290
-3% -$199K ﹤0.01% 2674
2020
Q4 		$8.02M Buy
237,047
+131,125
+124% +$3.76M ﹤0.01% 2395
2020
Q3 		$2.65M Sell
105,922
-4,930
-4% -$117K ﹤0.01% 2916
2020
Q2 		$3.74M Buy
+110,852
New +$3.54M ﹤0.01% 2691

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Northern Trust's ORIC Position: Q2 2026 in Review

Northern Trust increased its Oric Pharmaceuticals (ORIC) stake by 13% in Q2 2026, buying an estimated $865K and bringing the position to 806,304 shares worth $8.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2290.

Northern Trust first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. The position peaked at $10.7M in Q3 2025. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Northern Trust held 806,304 shares of Oric Pharmaceuticals worth $8.73M as of Q2 2026.
  • Northern Trust bought 95,443 Oric Pharmaceuticals shares in Q2 2026, an estimated $865K.
  • Oric Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2290 holding.
  • Northern Trust first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Northern Trust's Oric Pharmaceuticals position peaked at $10.7M in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.